Nama's AI scorecard currently rates iRhythm Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is IRTC's P/E ratio?

iRhythm trades at a trailing price-to-earnings ratio of 67.3.

When does IRTC report earnings?

iRhythm's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.21.

What is the IRTC price target?

The median analyst price target from 15 analysts is $175.00, with a range of $140.00 – $196.00.

Is IRTC Shariah compliant?

Nama's AAOIFI-style screen reads iRhythm as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

iRhythm (IRTC)

Healthcare · Medical Devices · NASDAQ

iRhythm (IRTC) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $2.97B, a trailing price-to-earnings ratio of 67.3 and a free-cash-flow yield of 1.2%. Over the most recent reported fiscal year, revenue grew 26.2%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Trailing · -40.8% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-57.4%

How far the last close sits under the highest price of the past five years.

Market cap	$2.97B
Trailing P/E	67.3
Price / book	16.0
Price / sales	3.6
FCF yield	1.2%
Dividend yield	—
Gross margin	71.5%
Operating margin	-1.1%
Net margin	-1.7%
Revenue growth (YoY)	+26.2%
Revenue growth (3-yr annual)	+22.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

IRTC earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.21). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.82	$0.05	+1540.0%	—
Q2 2026	Aug 6, 2026	$0.58	$0.04	+1350.0%	$224.17M
Q1 2026	Apr 30, 2026	-$0.35	-$0.64	+45.3%	$199.39M
Q4 2025	Feb 19, 2026	$0.29	$0.06	+383.3%	$208.89M

IRTC analyst price target

Median target $175.00 from 15 analysts, ranging $140.00 – $196.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live IRTC data on Nama Insights →

IRTC FAQ

Is IRTC a buy?: Nama's AI scorecard currently rates iRhythm Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is IRTC's P/E ratio?: iRhythm trades at a trailing price-to-earnings ratio of 67.3.
When does IRTC report earnings?: iRhythm's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.21.
What is the IRTC price target?: The median analyst price target from 15 analysts is $175.00, with a range of $140.00 – $196.00.
Is IRTC Shariah compliant?: Nama's AAOIFI-style screen reads iRhythm as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.